O'Shaughnessy Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

O'Shaughnessy Asset Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-4,538	Closed	-$413K	–	1619
2023 Q2	$413K	Buy	4,538 +399	+10%	+$34.4K	0.01%	953
2023 Q1	$273K	Buy	4,139 +5	+0.1%	+$289	﹤0.01%	1092
2022 Q4	$214K	Buy	4,134 +9	+0.2%	+$477	﹤0.01%	1089
2022 Q3	$282K	Buy	+4,125	New	+$244K	0.01%	955
2021 Q4	–	Sell	-3,006	Closed	-$99K	–	1319
2021 Q3	$99K	Buy	3,006 +537	+22%	+$30.2K	﹤0.01%	1371
2021 Q2	$156K	Buy	+2,469	New	+$127K	﹤0.01%	1140

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

O'Shaughnessy Asset Management's APLS Position: Q3 2023 in Review

O'Shaughnessy Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 4,538 shares — an estimated $413K sold.

O'Shaughnessy Asset Management first reported a position in APLS in Q2 2021 and held it in 6 quarters. The position peaked at $413K in Q2 2023. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

O'Shaughnessy Asset Management reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
O'Shaughnessy Asset Management sold 4,538 Apellis Pharmaceuticals shares in Q3 2023, an estimated $413K.
O'Shaughnessy Asset Management first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 6 quarters.
O'Shaughnessy Asset Management's Apellis Pharmaceuticals position peaked at $413K in Q2 2023.
256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on O'Shaughnessy Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.